1093403-37-2

Basic information

• Product Name: C₁₃H₁₁N₃O₅S₂
• Synonyms: C₁₃H₁₁N₃O₅S₂
• CAS NO: 1093403-37-2
• Molecular Weight: 353.379
• Mol File: 1093403-37-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: C₁₃H₁₁N₃O₅S₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₃H₁₁N₃O₅S₂(1093403-37-2)
• EPA Substance Registry System: C₁₃H₁₁N₃O₅S₂(1093403-37-2)

Safety Data

• Hazardous Substances Data: 1093403-37-2(Hazardous Substances Data)

Upstream product

• 6851-99-6 2-bromo-1-(2-nitrophenyl)ethanone 
• 912770-13-9 6-(2-nitro-phenyl)-imidazo[2,1-b]thiazole-3-carboxylic acid 
• 925437-85-0 (6-(2-nitrophenyl)imidazo[2,1-b]thiazol-3-yl)methanol 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 1120341-58-3 C₂₁H₂₅N₅O₄S 
• 1056562-54-9 2-(3-morpholin-4-ylmethyl-imidazo[2,1-b]thiazol-6-yl)-phenylamine 
• 925437-87-2 4-[6-(2-aminophenyl)imidazo[2,1-b]thiazol-3-ylmethyl]piperazine-1-carboxylic acid tert-butyl ester 
• 925437-89-4 C₁₄H₁₄N₄O₂S 
• 925436-46-0 C₃₀H₃₁N₇O₃S 
• 925434-55-5 SRT1720 
• 1093403-33-8 SRT₂₁₀₄ 
• 1449583-95-2 C₁₃H₁₂N₄O₂S 

Relevant articles and documents

Search for a novel SIRT1 activator: Structural modification of SRT1720 and biological evaluation

Syntheses and biological evaluation of novel SRT1720 derivatives are described in search for new candidates of SIRT1 activator. Several parts of the SRT1720 structure, including piperazine moiety, quinoxaline ring on the amide group, and position of the amide function, were modified, and the assay results indicated that transfer of the ortho amide-substituent regarding to the imidazo[1,2-b]thiazole core onto the meta position resulted in improvement of SIRT1 activation ability. Modeling analyses of SRT1720 and the most potent derivative bound to model complex of SIRT1 with peptide substrate were also performed.

SIRTUIN MODULATING IMIDAZOTHIAZOLE COMPOUNDS

Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.